What is it about?
Febuxostat is a xanthine oxidase inhibitor commonly used for the treatment of hyperuricemia in patients with gout. We present the case of a 65-year-old male patient who developed bone marrow suppression following 2 years of febuxostat therapy for the management of gout.
Featured Image
Photo by CDC on Unsplash
Why is it important?
Febuxostat, a non-purine selective inhibitor of xanthine oxidase, has emerged as an effective alternative to allopurinol
Perspectives
Febuxostat, a non-purine selective inhibitor of xanthine oxidase, has emerged as an effective alternative to allopurinol
Acquire Publications
Read the Original
This page is a summary of: Febuxostat Induced Pancytopenia, Journal of Case Reports and Medical History, September 2023, Acquire Publications LLC,
DOI: 10.54289/jcrmh2300125.
You can read the full text:
Contributors
The following have contributed to this page
